Compass Therapeutics, Inc.

NASDAQ:CMPX

Biotechnology

Healthcare
$0.61 -1.46%

-$0.03 today

Market cap
$110.03M
Beta
0.74
P/E (TTM)
-5.5
EPS (TTM)
-$0.37
52W Low $1.61High $6.88

Volume 1.79M

Average 7.64M

CMPX Long-term Debt

Borrowings due after more than one year.

Compass Therapeutics, Inc.NASDAQ: CMPX

Long-term Debt · Q1 FY2026 · quarter ended Mar 2026

Long-term debt remains negative

Q1 FY2026 long-term debt was $8.42M, compared with $0 a year earlier.

Context

  • Long-term debt amounted to 4.1% of total assets at the end of Q1 FY2026, up 4.1 pp from a year earlier.
  • Long-term debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.42M-4.7% QoQ
Last fiscal yearDec 2025
$8.83M— YoY
Year agoMar 2025
$0— since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
8.83M USD
Year-over-year change
—

Long-term Debt vs competitors

How CMPX compares with its peers on the latest reported figures

  • CMPX's Mar 2026 long-term debt of $8.42M is the 6th highest of the 11 companies compared; the peer median is $13.8M.
  • Long-term debt amounts to 4.1% of total assets for CMPX, versus a peer median of 9.7%.
CMPX Competitors Peer median
Long-term Debt for CMPX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OMEROmeros CorporationMar 2026$278.77M -20.1%-1.9%97.4%
GOSSGossamer Bio, Inc.Mar 2026$198.76M +0.5%-1.5%154.2%
KALVKalVista Pharmaceuticals, Inc.Dec 2025$139.23M ——41.5%
LXRXLexicon Pharmaceuticals, Inc.Mar 2026$49.68M -15.3%+0.6%18.5%
OCGNOcugen, Inc.Mar 2026$24.19M -12.6%+129.1%42.5%
CMPXCompass Therapeutics, Inc.Mar 2026$8.42M ——4.1%
FULCFulcrum Therapeutics, Inc.Mar 2026$3.41M -41.9%—1.0%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$406K ——0.2%
FDMT4D Molecular Therapeutics, Inc.Mar 2026$0 ——0.0%
MNPRMonopar Therapeutics Inc.Mar 2026$0 ——0.0%
BCYCBicycle Therapeutics plcMar 2026$0 ——0.0%
Peer median (excluding CMPX) $13.8M-15.3%-0.5%9.7%

Competitors are the stored peer set for CMPX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents144.51M34.95M24.23M43.48M30.64M
Short-term Investments0151.66M128.23M83.24M178.26M
Net Receivables00000
Inventory00000
Other Current Assets08.18M1.42M6.03M913K
Total Current Assets147.11M194.79M153.88M132.75M209.82M
Property, Plant & Equipment (Net)6.33M4.53M2.67M7.08M9.2M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets320K320K320K568K568K
Total Non-current Assets6.65M4.85M2.99M7.65M9.77M
Total Assets153.76M199.65M156.88M140.4M219.59M
Account Payables867K3.38M4.09M2.25M1.59M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.6M1.56M1.94M2.79M2.68M
Total Current Liabilities10.63M16.17M7.8M8.87M13.97M
Long-term Debt00008.83M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0001K0
Total Non-current Liabilities3.05M1.84M536K6.3M8.83M
Total Liabilities13.68M18.01M8.34M15.17M22.8M
Common Stock10K13K13K13K18K
Retained Earnings(233.59M)(272.81M)(315.31M)(364.68M)(431.17M)
Accumulated OCI0(302K)37K210K280K
Other Stockholders Equity(0)0000
Minority Interest00000
Total Equity140.08M181.64M148.54M125.23M196.79M
Total Debt4.04M2.94M1.73M6.63M9.83M
Net Debt(140.48M)(32.01M)(22.5M)(36.85M)(20.81M)

Compass Therapeutics, Inc.

NASDAQ:CMPX

Intrinsic Alpha fair value

Locked

Current Price

$0.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.